You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》花旗升微創醫療(00853.HK)評級至「買入」 上調目標價至66元
阿思達克 04-08 13:50
花旗發表研報指,微創醫療(00853.HK)去年度收入按年下跌18%,期內盈轉虧,錄得淨虧損1.91億美元,對比2019年度淨利為4,600萬美元;毛利率亦由2019年的71.1%下降至67.2%。

期內心血管介入產品業務收入按年下跌45%,公司解釋主要受疫情及集中採購政策調整價格所影響。去年骨科醫療器械業務中國地區收入增長10%,中國以外收入則下跌17%,管理層預期該業務今年復甦,目標收入增幅分別達到25%至30%及40%至45%。

管理層預期,今年總收入可反彈,恢復到約20%至25%的增長。該行對公司長期發展及成本優勢維持正面看法,有信心微創心通(02160.HK)分拆上市後可成為中國市場領先企業,相信公司接下來將分拆其他業務以釋放更多價值,將其評級由「中性/高風險」升至「買入/高風險」,目標價由34.96元上調至66元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account